Susquehanna International Group
NTLA icon

Susquehanna International Group’s Intellia Therapeutics NTLA Stock Holding History

Susquehanna International Group’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$21.4M Buy
1,667,800
+968,000
+138% +$12.3M ﹤0.01% 2143
2025
Q4 		$6.29M Buy
699,800
+390,200
+126% +$5.37M ﹤0.01% 3676
2025
Q3 		$5.35M Buy
309,600
+79,800
+35% +$983K ﹤0.01% 3978
2025
Q2 		$2.16M Buy
229,800
+140,000
+156% +$1.15M ﹤0.01% 5636
2025
Q1 		$638K Buy
89,800
+16,400
+22% +$166K ﹤0.01% 8364
2024
Q4 		$856K Sell
73,400
-16,100
-18% -$251K ﹤0.01% 7358
2024
Q3 		$1.84M Sell
89,500
-207,400
-70% -$4.78M ﹤0.01% 5426
2024
Q2 		$6.64M Buy
296,900
+40,600
+16% +$967K ﹤0.01% 3006
2024
Q1 		$7.05M Buy
256,300
+18,700
+8% +$519K ﹤0.01% 3116
2023
Q4 		$7.24M Buy
237,600
+131,400
+124% +$3.78M ﹤0.01% 3110
2023
Q3 		$3.36M Sell
106,200
-6,900
-6% -$268K ﹤0.01% 4188
2023
Q2 		$4.61M Buy
113,100
+4,000
+4% +$162K ﹤0.01% 3672
2023
Q1 		$4.07M Buy
109,100
+16,400
+18% +$643K ﹤0.01% 3768
2022
Q4 		$3.23M Sell
92,700
-116,000
-56% -$5.52M ﹤0.01% 3888
2022
Q3 		$11.7M Buy
208,700
+116,100
+125% +$7.2M ﹤0.01% 1965
2022
Q2 		$4.79M Sell
92,600
-16,100
-15% -$818K ﹤0.01% 3255
2022
Q1 		$7.9M Buy
108,700
+3,000
+3% +$254K ﹤0.01% 2877
2021
Q4 		$12.5M Sell
105,700
-16,800
-14% -$2.1M ﹤0.01% 2422
2021
Q3 		$16.4M Sell
122,500
-139,900
-53% -$21.2M ﹤0.01% 2201
2021
Q2 		$42.5M Buy
262,400
+30,400
+13% +$2.37M 0.01% 1317
2021
Q1 		$18.6M Buy
232,000
+167,600
+260% +$11.2M ﹤0.01% 1964
2020
Q4 		$3.5M Buy
64,400
+3,400
+6% +$123K ﹤0.01% 4045
2020
Q3 		$1.21M Sell
61,000
-27,900
-31% -$582K ﹤0.01% 5652
2020
Q2 		$1.87M Buy
88,900
+43,300
+95% +$736K ﹤0.01% 4624
2020
Q1 		$558K Buy
45,600
+34,600
+315% +$466K ﹤0.01% 6686
2019
Q4 		$161K Sell
11,000
-16,200
-60% -$225K ﹤0.01% 8904
2019
Q3 		$363K Sell
27,200
-2,300
-8% -$36.7K ﹤0.01% 7912
2019
Q2 		$483K Sell
29,500
-36,900
-56% -$580K ﹤0.01% 7340
2019
Q1 		$1.13M Sell
66,400
-16,400
-20% -$244K ﹤0.01% 4805
2018
Q4 		$1.13M Buy
82,800
+23,200
+39% +$431K ﹤0.01% 4447
2018
Q3 		$1.71M Sell
59,600
-72,800
-55% -$2.12M ﹤0.01% 4257
2018
Q2 		$3.62M Buy
132,400
+7,000
+6% +$170K ﹤0.01% 3129
2018
Q1 		$2.65M Buy
125,400
+83,200
+197% +$2.05M ﹤0.01% 3449
2017
Q4 		$811K Buy
42,200
+2,500
+6% +$57.7K ﹤0.01% 5659
2017
Q3 		$987K Buy
39,700
+12,900
+48% +$243K ﹤0.01% 5286
2017
Q2 		$429K Buy
+26,800
New +$374K ﹤0.01% 6928

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $47.9M AUM 29.29% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Susquehanna International Group's NTLA Position: Q1 2026 in Review

Susquehanna International Group reduced its Intellia Therapeutics (NTLA) stake by 14% in Q1 2026, selling an estimated $1.11M and leaving 521,465 shares worth $6.69M. The position accounts for ﹤0.01% of the portfolio, ranked #3747.

Susquehanna International Group first reported a position in NTLA in Q4 2016 and has held it in 34 quarters since. The position peaked at $15.4M in Q3 2025. 303 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Susquehanna International Group held 521,465 shares of Intellia Therapeutics worth $6.69M as of Q1 2026.
  • Susquehanna International Group sold 87,200 Intellia Therapeutics shares in Q1 2026, an estimated $1.11M.
  • Intellia Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #3747 holding.
  • Susquehanna International Group first reported a position in Intellia Therapeutics in Q4 2016 and has held it in 34 quarters since.
  • Susquehanna International Group's Intellia Therapeutics position peaked at $15.4M in Q3 2025.
  • 303 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.